October 10, 2023 07:16 AM EDTUpdated 12:49 PM
R&D

Im­mu­nic touts PhII bio­mark­er da­ta for mul­ti­ple scle­ro­sis drug

Katherine Lewin

News Reporter

New York-based biotech Im­mu­nic re­leased in­ter­im Phase II da­ta Mon­day show­ing its lead can­di­date for pro­gres­sive mul­ti­ple scle­ro­sis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times